Search results
Results from the WOW.Com Content Network
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
Preference-based PROs can be used for the computation of a quality-adjusted life year. A preference based PRO has an algorithm attached to the PRO instrument which can 'weigh' the outcomes reported by patients according to the preferences for health outcomes of a group of individuals such as the general public or of patient groups.
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
Iowa is now No. 2 in cancer incidence in the country, and our rates are rising. Between pesticide use and the exponential growth of Concentrated Animal Feeding Operations, or CAFOs, nitrate levels ...
The estrogen diethylstilbestrol (DES) is occasionally used to treat prostate cancer through suppression of testosterone production. It was previously used in the treatment of breast cancer, but has been replaced by more effective and less toxic agents. Estrace is an estrogen which was also formerly used for antiandrogen therapy of prostate ...
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. Doctors share what patients should know about the drug.
As of August 2014, a clinical trial administering sipuleucel-T in conjunction with ipilimumab (Yervoy) was tracking subjects but no longer enrolling new subjects; the trial evaluates the clinical safety and anti-cancer effects (quantified in PSA, radiographic and T cell response) of the combination therapy in patients with advanced prostate cancer.